Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115493962> ?p ?o ?g. }
- W3115493962 endingPage "30" @default.
- W3115493962 startingPage "1" @default.
- W3115493962 abstract "The Royal Australian and New Zealand College of Psychiatrists is co-ordinating the development of clinical practice guidelines (CPGs) in psychiatry, funded under the National Mental Health Strategy (Australia) and the New Zealand Health Funding Authority. This paper presents CPGs for schizophrenia and related disorders. Over the past decade schizophrenia has become more treatable than ever before. A new generation of drug therapies, a renaissance of psychological and psychosocial interventions and a first generation of reform within the specialist mental health system have combined to create an evidence-based climate of realistic optimism. Progressive neuroscientific advances hold out the strong possibility of more definitive biological treatments in the near future. However, this improved potential for better outcomes and quality of life for people with schizophrenia has not been translated into reality in Australia. The efficacy-effectiveness gap is wider for schizophrenia than any other serious medical disorder. Therapeutic nihilism, under-resourcing of services and a stalling of the service reform process, poor morale within specialist mental health services, a lack of broad-based recovery and life support programs, and a climate of tenacious stigma and consequent lack of concern for people with schizophrenia are the contributory causes for this failure to effectively treat. These guidelines therefore tackle only one element in the endeavour to reduce the impact of schizophrenia. They distil the current evidence-base and make recommendations based on the best available knowledge.A comprehensive literature review (1990-2003) was conducted, including all Cochrane schizophrenia reviews and all relevant meta-analyses, and a number of recent international clinical practice guidelines were consulted. A series of drafts were refined by the expert committee and enhanced through a bi-national consultation process.This guideline provides evidence-based recommendations for the management of schizophrenia by treatment type and by phase of illness. The essential features of the guidelines are: (i) Early detection and comprehensive treatment of first episode cases is a priority since the psychosocial and possibly the biological impact of illness can be minimized and outcome improved. An optimistic attitude on the part of health professionals is an essential ingredient from the outset and across all phases of illness. (ii) Comprehensive and sustained intervention should be assured during the initial 3-5 years following diagnosis since course of illness is strongly influenced by what occurs in this 'critical period'. Patients should not have to 'prove chronicity' before they gain consistent access and tenure to specialist mental health services. (iii) Antipsychotic medication is the cornerstone of treatment. These medicines have improved in quality and tolerability, yet should be used cautiously and in a more targeted manner than in the past. The treatment of choice for most patients is now the novel antipsychotic medications because of their superior tolerability and, in particular, the reduced risk of tardive dyskinesia. This is particularly so for the first episode patient where, due to superior tolerability, novel agents are the first, second and third line choice. These novel agents are nevertheless associated with potentially serious medium to long-term side-effects of their own for which patients must be carefully monitored. Conventional antipsychotic medications in low dosage may still have a role in a small proportion of patients, where there has been full remission and good tolerability; however, the indications are shrinking progressively. These principles are now accepted in most developed countries. (vi) Clozapine should be used early in the course, as soon as treatment resistance to at least two antipsychotics has been demonstrated. This usually means incomplete remission of positive symptomatology, but clozapine may also be considered where there are pervasive negative symptoms or significant or persistent suicidal risk is present. (v) Comprehensive psychosocial interventions should be routinely available to all patients and their families, and provided by appropriately trained mental health professionals with time to devote to the task. This includes family interventions, cognitive-behaviour therapy, vocational rehabilitation and other forms of therapy, especially for comorbid conditions, such as substance abuse, depression and anxiety. (vi) The social and cultural environment of people with schizophrenia is an essential arena for intervention. Adequate shelter, financial security, access to meaningful social roles and availability of social support are essential components of recovery and quality of life. (vii) Interventions should be carefully tailored to phase and stage of illness, and to gender and cultural background. (viii) Genuine involvement of consumers and relatives in service development and provision should be standard. (ix) Maintenance of good physical health and prevention and early treatment of serious medical illness has been seriously neglected in the management of schizophrenia, and results in premature death and widespread morbidity. Quality of medical care for people with schizophrenia should be equivalent to the general community standard. (x) General practitioners (GPs)s should always be closely involved in the care of people with schizophrenia. However, this should be truly shared care, and sole care by a GP with minimal or no specialist involvement, while very common, is not regarded as an acceptable standard of care. Optimal treatment of schizophrenia requires a multidisciplinary team approach with a consultant psychiatrist centrally involved." @default.
- W3115493962 created "2021-01-05" @default.
- W3115493962 creator A5011342866 @default.
- W3115493962 creator A5013031947 @default.
- W3115493962 creator A5013937293 @default.
- W3115493962 creator A5019214809 @default.
- W3115493962 creator A5019391929 @default.
- W3115493962 creator A5020568225 @default.
- W3115493962 creator A5033388628 @default.
- W3115493962 creator A5038594703 @default.
- W3115493962 creator A5042993723 @default.
- W3115493962 creator A5047022638 @default.
- W3115493962 creator A5055206375 @default.
- W3115493962 creator A5058238831 @default.
- W3115493962 creator A5058926155 @default.
- W3115493962 creator A5059967833 @default.
- W3115493962 creator A5069662422 @default.
- W3115493962 creator A5077945782 @default.
- W3115493962 creator A5086610325 @default.
- W3115493962 date "2005-01-01" @default.
- W3115493962 modified "2023-10-16" @default.
- W3115493962 title "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders" @default.
- W3115493962 cites W104003269 @default.
- W3115493962 cites W105133888 @default.
- W3115493962 cites W10562547 @default.
- W3115493962 cites W1206579674 @default.
- W3115493962 cites W1270515817 @default.
- W3115493962 cites W134775781 @default.
- W3115493962 cites W1499727415 @default.
- W3115493962 cites W1523531092 @default.
- W3115493962 cites W153652483 @default.
- W3115493962 cites W1616286551 @default.
- W3115493962 cites W1964040992 @default.
- W3115493962 cites W1964391934 @default.
- W3115493962 cites W1964616687 @default.
- W3115493962 cites W1964927909 @default.
- W3115493962 cites W1965111165 @default.
- W3115493962 cites W1967674108 @default.
- W3115493962 cites W1973871544 @default.
- W3115493962 cites W1975323478 @default.
- W3115493962 cites W1978251978 @default.
- W3115493962 cites W1978752073 @default.
- W3115493962 cites W1980174047 @default.
- W3115493962 cites W1981639800 @default.
- W3115493962 cites W1985472130 @default.
- W3115493962 cites W1987547553 @default.
- W3115493962 cites W1989113721 @default.
- W3115493962 cites W1993773066 @default.
- W3115493962 cites W1996254896 @default.
- W3115493962 cites W1997079708 @default.
- W3115493962 cites W1997205347 @default.
- W3115493962 cites W2000269219 @default.
- W3115493962 cites W2001478878 @default.
- W3115493962 cites W2014022579 @default.
- W3115493962 cites W2017457759 @default.
- W3115493962 cites W2021747099 @default.
- W3115493962 cites W2024643973 @default.
- W3115493962 cites W2026981656 @default.
- W3115493962 cites W2036215425 @default.
- W3115493962 cites W2036563231 @default.
- W3115493962 cites W2038344802 @default.
- W3115493962 cites W2041474698 @default.
- W3115493962 cites W2041486022 @default.
- W3115493962 cites W2046493983 @default.
- W3115493962 cites W2049907076 @default.
- W3115493962 cites W2050958586 @default.
- W3115493962 cites W2051543041 @default.
- W3115493962 cites W2055540161 @default.
- W3115493962 cites W2057156751 @default.
- W3115493962 cites W2059917054 @default.
- W3115493962 cites W2064163179 @default.
- W3115493962 cites W2066357241 @default.
- W3115493962 cites W2069947866 @default.
- W3115493962 cites W2071671065 @default.
- W3115493962 cites W2074311597 @default.
- W3115493962 cites W2075098245 @default.
- W3115493962 cites W2078717479 @default.
- W3115493962 cites W2081069399 @default.
- W3115493962 cites W2081235876 @default.
- W3115493962 cites W2082452572 @default.
- W3115493962 cites W2083002964 @default.
- W3115493962 cites W2084200905 @default.
- W3115493962 cites W2084315910 @default.
- W3115493962 cites W2087687048 @default.
- W3115493962 cites W2088281647 @default.
- W3115493962 cites W2088572669 @default.
- W3115493962 cites W2089182563 @default.
- W3115493962 cites W2090778982 @default.
- W3115493962 cites W2096635847 @default.
- W3115493962 cites W2098132738 @default.
- W3115493962 cites W2099920076 @default.
- W3115493962 cites W2101762862 @default.
- W3115493962 cites W2103593066 @default.
- W3115493962 cites W2103851709 @default.
- W3115493962 cites W2107406184 @default.
- W3115493962 cites W2107544837 @default.
- W3115493962 cites W2108069427 @default.
- W3115493962 cites W2109179110 @default.